William Feehery

LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.